Jayarama-Naidu Roopa, Johannes Jörg, Meyer Franziska, Wirth Eva Katrin, Schomburg Lutz, Köhrle Josef, Renko Kostja
Institut für Experimentelle Endokrinologie, Charité - Universitätsmedizin Berlin, D-13353 Berlin, Germany.
Endocrinology. 2015 Jul;156(7):2739-45. doi: 10.1210/en.2015-1016. Epub 2015 Apr 24.
Thyroid hormones (TH) are actively taken up into target cells via TH-transmembrane transporters (THTT). Their activity and expression patterns define a layer of endocrine regulation that is poorly understood. Therefore, THTT are potential targets for interfering agents (endocrine disruptors) as well as for pharmacological interventions. Inactivating mutations have been identified as the underlying cause of heritable diseases (monocarboxylate transporter 8-associated Allan-Herndon-Dudley syndrome) and might also define a class of subclinical TH insensitivity. As a basic tool to solve questions regarding THTT substrate specificity, activation or inactivation by compounds and functional changes from mutations, uptake assays with radiolabeled tracers are standard. Due to the need for radioactive isotopes, this technique is limited to screening of labelled substrates and disadvantageous regarding handling, setup, and regulatory issues. To overcome these hurdles, we developed an uptake assay protocol using nonradioactive ligands. In brief, uptake of nonradioactive iodine-containing substrate molecules was monitored via Sandell-Kolthoff reaction. The novel assay was designed to the common microtiter plate layout. As a prove-of-principle, we measured TH uptake by monocarboxylate transporter 8-transfected MDCK1 cells. Titrations with bromosulphthalein as an example for inhibitor screening setups and a side-by-side comparison with the radioactive method prove this assay to be reliable, sensitive, and convenient. Furthermore, the method was applicable on primary murine astrocytes, which enables high-throughput screening studies on in vitro model systems with physiological transporter regulation. Due to its design, it is applicable for high-throughput screening of modulatory compounds, but it is also a safe, inexpensive and an easily accessible method for functional testing of THTT in basic science.
甲状腺激素(TH)通过甲状腺激素跨膜转运体(THTT)被主动摄取到靶细胞中。它们的活性和表达模式定义了一层内分泌调节,而这一层调节目前还知之甚少。因此,THTT是干扰剂(内分泌干扰物)以及药物干预的潜在靶点。失活突变已被确定为遗传性疾病(单羧酸转运体8相关的艾伦 - 赫恩登 - 达德利综合征)的根本原因,并且可能还定义了一类亚临床甲状腺激素不敏感。作为解决有关THTT底物特异性、化合物激活或失活以及突变引起的功能变化等问题的基本工具,使用放射性示踪剂的摄取测定是标准方法。由于需要放射性同位素,该技术仅限于对标记底物的筛选,并且在处理、设置和监管问题方面存在劣势。为了克服这些障碍,我们开发了一种使用非放射性配体的摄取测定方案。简而言之,通过桑德尔 - 科尔托夫反应监测非放射性含碘底物分子的摄取。这种新型测定方法设计为适用于常见的微量滴定板布局。作为原理验证,我们测量了单羧酸转运体8转染的MDCK1细胞对甲状腺激素的摄取。以溴磺酞为例进行抑制剂筛选设置的滴定以及与放射性方法的并行比较证明该测定方法可靠、灵敏且方便。此外,该方法适用于原代小鼠星形胶质细胞,这使得能够在具有生理转运体调节的体外模型系统上进行高通量筛选研究。由于其设计,它适用于调节化合物的高通量筛选,但它也是一种用于基础科学中THTT功能测试的安全、廉价且易于获得的方法。